Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
William Blair, a global investment banking and asset management firm, is pleased to announce the expansion of its global biopharmaceuticals franchise. John Sonnier, formerly an equity research analyst at William Blair, is joining the firm’s investment banking team as a managing director. Mr. Sonnier will partner with the firm’s veteran biopharma bankers to provide capital markets and M&A advisory services.
|
|||
Mr. Sonnier joined William Blair in 2005 to build the firm’s biopharma equity research practice. Before coming to William Blair, Mr. Sonnier was a biotechnology equity research analyst for seven years with the Prudential Equity Group; previously, he spent eight years in various commercial and strategic roles at Johnson & Johnson and Baxter International. Mr. Sonnier holds a Master of Public Health degree from Johns Hopkins University.
“Given heightened consolidation, increasing capital needs, and uncertainty around healthcare policy, the biopharma industry’s need for trusted strategic advice and access to capital markets is greater now than ever before,” said Brent Gledhill, William Blair’s global head of investment banking. “As our biopharma franchise continues to expand, John Sonnier significantly adds to the depth of our sector expertise and enhances our ability to deliver optimal outcomes for our clients.”
Since 2014, William Blair’s healthcare investment banking team has achieved significant success, having completed more than 200 M&A assignments and equity offerings across the industry. This includes transactions for leading biopharma companies around the world.
“As the pace of innovation across the life sciences industry accelerates, I am excited about the opportunity to work with William Blair’s world-class investment banking team to help high-growth biopharma companies access strategic capital,” Mr. Sonnier said.
About William Blair Investment Banking
William Blair’s investment banking group enables corporations, financial sponsors, and owner/entrepreneurs around the world to achieve their growth, liquidity, and financing objectives. Drawing on the collective intellectual capital and deep sector expertise of a global team that reaches across more than 20 cities on five continents, the investment banking group brings a rigorous and innovative approach to corporate board advisory projects, mergers and acquisitions, and equity and debt financing. From 2012 to 2016, the team advised on more than $230 billion in completed transaction volume. For more information, please visit williamblair.com.
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/4c11833a-7fc4-43df-aff8-069549de888a
Tony Zimmer William Blair & Company 312-364-8611 [email protected]
